-
No. 1 Flonase to face strong competition
The allergy space will continue to heat up significantly in 2017 as marketers pollinate the airwaves with advertisements promoting their latest brand introductions. GSK Consumer Healthcare will have its hands full defending the Flonase franchise, now the No. 1 allergy remedy on the market. Not only is there another nasal corticosteroid on the market — McNeil Consumer’s Rhinocort launched earlier this year — but Flonase faces increasing private-label and brand competition.
-
Innovation, performance, value keys to foot care
The foot care category is still dominated by Bayer Consumer’s Dr Scholl’s, which generated $291.9 million in sales for the 52 weeks ended June 4, on a 6.8% decline, according to Nielsen data as provided by Implus. Store brands gained 7.4% in that time frame to $65.6 million, and Implus gained 47.5% with the Airplus brand to $40.7 million.